Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Cancers|July 20, 2019
Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell CarcinomaViola J Chen, Gabriela Hernandez-Meza, Prashasti Agrawal, et al.
Urologic Oncology|June 29, 2020
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancerHriday P Bhambhvani, Alvaro Zamora, Eugene Shkolyar, et al.
The American Journal of Surgical Pathology|April 28, 2025
Renal Epithelioid Angiomyolipoma: Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic FeaturesAnkur R Sangoi, Anandi Lobo, Shilpy Jha, et al.
European Urology|March 8, 2016
Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?Philip V Barbosa, I-Chun Thomas, Sandy Srinivas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2013
NCCN Task Force Report: Bone Health In Cancer CareJulie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
European Urology|April 18, 2017
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell CarcinomaSumanta K Pal, Guru Sonpavde, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN Task Force Report: Bone Health in Cancer CareJulie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Cancers|July 20, 2019
Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell CarcinomaViola J Chen, Gabriela Hernandez-Meza, Prashasti Agrawal, et al.
Urologic Oncology|June 29, 2020
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancerHriday P Bhambhvani, Alvaro Zamora, Eugene Shkolyar, et al.
The American Journal of Surgical Pathology|April 28, 2025
Renal Epithelioid Angiomyolipoma: Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic FeaturesAnkur R Sangoi, Anandi Lobo, Shilpy Jha, et al.
European Urology|March 8, 2016
Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?Philip V Barbosa, I-Chun Thomas, Sandy Srinivas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 3, 2013
NCCN Task Force Report: Bone Health In Cancer CareJulie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancerRonald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
European Urology|April 18, 2017
Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell CarcinomaSumanta K Pal, Guru Sonpavde, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN Task Force Report: Bone Health in Cancer CareJulie R Gralow, J Sybil Biermann, Azeez Farooki, et al.
Pageof 16